Clinical and regulatory intelligence for T-cell Acute Lymphoblastic Leukemia with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 0
Assets: 1

Relevant assets

Isatuximab →

Relevant companies

Sanofi →

Recent signals(2)

ClinicalJune 22, 2026

Isatuximab Trial for Relapsed/Refractory CD38 Positive T-ALL Initiated

A new trial is evaluating Isatuximab in adult patients with relapsed/refractory CD38 positive T-cell acute lymphoblastic leukemia, focusing on two treatment cohorts.

ClinicalJune 21, 2026

Phase 1 Study of Venetoclax Combination in T-Cell Acute Lymphoblastic Leukemia

A Phase 1 study is underway evaluating a combination of Venetoclax, Dexamethasone, Bortezomib, and Daratumumab in adolescents and young adults with relapsed or refractory T-ALL or T-LBL.

Upcoming catalysts

No catalysts indexed for this entity yet.

Therapeutic areas

Oncology →

T-cell Acute Lymphoblastic Leukemia →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.